期刊文献+

miR146a及miR155表达与益赛普治疗类风湿关节炎疗效及安全性的相关性研究 被引量:7

Study on the Correlation Between the Expression Level of miR146a and miR155 and the Effect and Safety of Yisaipu in the Treatment of Rheumatoid Arthritis
下载PDF
导出
摘要 目的探讨类风湿关节炎(RA)患者外周血单个核细胞(PBMC)中miR146a及miR155的表达与益赛普治疗RA疗效的相关性。方法 117例中国RA患者接受了为期3个月的益赛普治疗,以欧洲抗风湿病联盟与美国风湿病学学会共同修订的RA临床缓解新标准评估益赛普对RA的疗效。采用实时荧光定量逆转录聚合酶链反应法检测PBMC中miR146a及miR155的表达水平,并分析miR146a及miR155的表达水平与益赛普治疗RA疗效的相关性。结果治疗后,临床缓解91例,26例患者未达到临床缓解新标准。临床缓解患者PBMC中miR146a的表达水平显著低于未达到临床缓解患者[(1.30±0.62)比(1.59±0.56),P<0.05],而两组患者miR155的表达水平无显著性差异[(1.87±0.46)比(1.83±0.33),P>0.05]。结论治疗前,PBMC中miR146a的表达水平与益赛普治疗RA的疗效可能相关,具有较低miR146a表达水平的RA患者对益赛普的疗效反应较好,有可能作为益赛普对RA的疗效预测指标,具体作用机制尚需作进一步研究。 Objective To investigate the correlation between the expression level of miR-146a and miR155 in peripheral blood mononuclear cells(PBMCs)in patients with rheumatoid arthritis(RA)and the effect of Yisaipu in the treatment of RA.Methods Totally 117 patients with RA in China received the treatment of Yisaipu for 3 months,the clinical effect of Yisaipu in the treatment of RA was evaluated by new standard of ACR/EULAR definition of clinical remission in RA,the expression levels of miR-146a and miR155 in PBMCs of RA patients were determined by quantitative realtime RT-polymerase chain reaction(RT-PCR),the correlation between the expression level of miR-146a and miR155 and the effect of Yisaipu in the treatment of RA was analyzed.Results After treat-ment,91 patients cases were remission,and 26 patients failed to meet the new standard of clinical remission.The expression level of miR 146a in the PBMC of the patients with clinical remission was significantly lower than that of patients who failed to meet clinical remission[(1.30±0.62)vs.(1.59±0.56),P<0.05].However,there was no significant difference in the expression level of miR155 in the two groups[(1.87±0.46)vs.(1.83±0.33),P>0.05].Conclusion Before treatment,the expression level of miR146a in PBMCs may be related to the efficacy of Yisaipu in the treatment of RA,the RA patients with lower expression levels of miR146a have better effect response to Yisaipu,the expression level of miR146a may be used as a predictor of curative effect of Yisaipu on RA,and the specific mechanism needs further study.
作者 佘若男 李博 胡秋侠 吴系美 谭锦辉 胡建云 唐群芳 汪小平 She Ruonan;Li Bo;Hu Qiuxia;Wu Ximei;Tan Jinhui;Hu Jianyun;Tang Qunfang;Wang Xiaoping(Department of Rheumatology,The People′s Hospital of Longhua District in Shenzhen City,Shenzhen,Guangdong,China 518109)
出处 《中国药业》 CAS 2018年第7期24-26,共3页 China Pharmaceuticals
基金 广东省医学科研基金立项课题[A2013611] 广东省深圳市卫生计生系统科研项目(医疗卫生类)[201501051] 广东省深圳市科技计划项目(医疗卫生类)[201601060] 广东省深圳市龙华区科技创新资金项目(医疗卫生类)[20150924A1030103]
关键词 miR146a miR155 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 益赛普 类风湿关节炎 外周血单个核细胞 相关性 疗效 miR-146a miR155 recombinant human tumor necrosis factor receptor classⅡ-antibody confused protein Yisaipu rheumatoid arthritis peripheral blood mononuclear cells correlation curative effect
  • 相关文献

参考文献2

二级参考文献24

  • 1胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量:86
  • 2K. L. Hyrieh, K. D. Watson, A. J. Silman, et al. Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: resuits from the British Society for Rheumatology Biologics Register [J].Rheumatology ,2006, 45:1558-1565.
  • 3M. Seitz, U. Wirthmu ller, B. Mu ller, et al. The -308 tumour necrosis factorgene polymorphism predicts therapeutic response to TNF-a blockers in rheumatoid arthritis and spondyloarthritis patients [J]. Rheumatology ,2007, 46(1):93-96.
  • 4Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IlIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents[J]. Arthritis Rheum, 2005, 52(9):2693-2696.
  • 5Rahman MU, Strusberg I, Geusens P, et al. Doubleblinded infliximab dose escalation in patients with rheumatoid arthritis [J]. Ann Rheum Dis ,2007,66(9):1233-1238.
  • 6Vander Cruyssen B, Van Looy S, Wyns B, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity [J]. Arthritis Research & Therapy ,2006, 8:R112.
  • 7Kristensen LE, Kapetanovic MC, Gu lfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register [J]. Rheumatology (Oxford),2008;47(4): 495-499.
  • 8Shealy DJ,Wooley PH,Emmell E,et al.Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice.Arthritis Res,2002,4:R7.
  • 9Siegel SA,Shealy DJ,Nakada MT,et al.The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.Cytokine,1995,1:15-25.
  • 10D'Haens DR.Infliximab as disease-modifying therapy.Eur'J Gastroenterol Hepatol,2003,15:233-237.

共引文献38

同被引文献67

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部